WO2021027192A1 - 给药管、给药装置及神经精神疾病治疗系统 - Google Patents

给药管、给药装置及神经精神疾病治疗系统 Download PDF

Info

Publication number
WO2021027192A1
WO2021027192A1 PCT/CN2019/123177 CN2019123177W WO2021027192A1 WO 2021027192 A1 WO2021027192 A1 WO 2021027192A1 CN 2019123177 W CN2019123177 W CN 2019123177W WO 2021027192 A1 WO2021027192 A1 WO 2021027192A1
Authority
WO
WIPO (PCT)
Prior art keywords
tube
tube body
drug delivery
outer diameter
inner diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/123177
Other languages
English (en)
French (fr)
Inventor
王璐璐
鲁艺
钟成
曹燚
潘苏婉
王立平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Institute of Advanced Technology of CAS
Original Assignee
Shenzhen Institute of Advanced Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Advanced Technology of CAS filed Critical Shenzhen Institute of Advanced Technology of CAS
Publication of WO2021027192A1 publication Critical patent/WO2021027192A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • This application relates to the technical fields of medical equipment, neuroscience, etc., in particular to a drug delivery tube, drug delivery device and neuropsychiatric disease treatment system.
  • optogenetics and pharmacogenetics are commonly used in order to achieve regulation of specific cell types in specific brain regions.
  • pharmacogenetics we need to inject viruses specifically expressed on specific types of neurons into the brains of experimental animals in advance. After four weeks of expression, a drug delivery tube was implanted above the brain area studied in experimental animals, and the micro-injection pump was used to inject drugs into the brain to achieve specific regulation of the brain area.
  • the purpose of this application is to provide a drug delivery tube, drug delivery device and neuropsychiatric disease treatment system to alleviate at least one of the above-mentioned problems.
  • the present application provides a drug delivery tube, including: a first tube body and a second tube body that are hermetically connected to each other;
  • the first tube body is used to be implanted into the brain area, and the outer diameter of the first tube body is in the range of 350-360 ⁇ m, and the inner diameter is in the range of 180-190 ⁇ m;
  • the second tube body is used to connect with the drug delivery device, the hardness of the second tube body is less than the hardness of the first tube body, and the inner diameter of the second tube body is not less than that of the first tube body. Outer diameter.
  • the outer diameter of the second tube body is in the range of 900-1100 ⁇ m, and the inner diameter is in the range of 450-550 ⁇ m.
  • the outer diameter of the first tube body is 356 ⁇ m, and the inner diameter is 182 ⁇ m;
  • the outer diameter of the second tube body is 1000 ⁇ m, and the inner diameter is 500 ⁇ m.
  • one end of the first tube body can be inserted into the second tube body, and the depth of the first tube body inserted into the second tube body is 5 mm.
  • first tube body and the second tube body are connected by a sealant.
  • cut length dimension of the first tube body is 1 cm larger than the depth dimension of the implanted brain region
  • the cut length of the second tube body is 3 cm.
  • the first tube body is a silicon tube, a glass tube or a polymer tube, preferably a silicon tube;
  • the second tube body is a plastic tube or a rubber tube, preferably a rubber tube.
  • the drug delivery device at least includes a syringe, and the output end of the syringe is used to connect with the end of the second tube away from the first tube.
  • the application provides a drug delivery device, including the drug delivery tube.
  • the application provides a neuropsychiatric disease treatment system, including the drug delivery device;
  • it includes an electrophysiological recording device and a drug delivery device;
  • Electrophysiological recording devices include electrophysiological recording devices, light stimulation devices and drug delivery devices.
  • the first tube is used for implantation in the brain area. Due to its small size, the outer diameter range is only 350-360 ⁇ m, and the inner diameter range is only 180-190 ⁇ m. One section is very thin, so the damage to the brain tissue after implantation will be minimal.
  • the second tube body is located outside the brain, and its inner diameter is not less than the outer diameter of the first tube body, and since the first tube body needs to be connected to the second tube body, the inner diameter of the second tube body is the same as that of the first tube body.
  • the difference between the outer diameters of the body will not be too large to ensure a sealed connection between the two; in addition, because the tube wall of the second tube body will not be too thick, the outer diameter of the second tube body will be relatively small. Therefore, the drug delivery tube provided by the present application can be implanted into multiple brain regions at the same time, which meets the requirement of simultaneously administering drugs to multiple brain regions.
  • the drug delivery tube only includes a first tube body and a second tube body that are sealed and connected to each other, so that the overall structure of the drug delivery tube is simple and the cost is low, and in use, due to the simple structure, it is easy to operate. It is also more convenient.
  • the drug delivery device provided by the present application includes the drug delivery tube described above. Therefore, the technical advantages achieved by the drug delivery device include the technical advantages achieved by the drug delivery tube described above, which will not be repeated here.
  • the neuropsychiatric disease treatment system includes the above-mentioned drug delivery device.
  • it may also include at least one of an electrophysiological recording device and a light stimulation device. Therefore, in addition to the technology achieved by the foregoing drug delivery device
  • it can also be combined with optical fiber for optical stimulation or different kinds of electrodes for electrophysiological recording, or even combined for optical stimulation and electrophysiological recording at the same time, making the application range wider.
  • Fig. 1 is a schematic diagram of the structure of a drug delivery tube provided in an embodiment of the application.
  • Icon 100-first tube body; 200-second tube body.
  • This embodiment provides a drug delivery tube, which includes a first tube body 100 and a second tube body 200 that are hermetically connected to each other;
  • the first tube 100 is used to be implanted into the brain area, the outer diameter of the first tube 100 ranges from 350-360 ⁇ m, and the inner diameter ranges from 180-190 ⁇ m;
  • the second tube body 200 is used to connect with the drug delivery device, the hardness of the second tube body 200 is less than the hardness of the first tube body 100, and the inner diameter of the second tube body 200 is not less than the outer diameter of the first tube body 100.
  • the drug delivery tube in this embodiment includes a first tube body 100 and a second tube body 200 that are connected to each other.
  • the first tube body 100 is implanted into a section of the brain, and a section is left exposed. Outside the brain, since the outer diameter of the first tube body 100 is relatively small, it is easy to implant in the brain, and the section exposed outside the brain is easy to fix.
  • the second tube 200 is completely exposed out of the brain, and the end of the second tube 200 that is not connected to the first tube 100 is combined with a small amount of drug delivery device. In this way, the drug can be delivered by the drug delivery device. Inject into the brain area through the second catheter and the first catheter in turn.
  • both the first tube body 100 and the second tube body 200 adopt a thin tube structure, and these two kinds of thin tubes can also be used as existing finished products, or directly purchased, or customized. The specific circumstances require the experimenter to follow You can design your own experiment requirements.
  • the first tube body 100 and a certain length of the second tube body 200 cut a certain length of the first tube body 100 and a certain length of the second tube body 200, and then connect one end of the first tube body 100 and the second tube body 200 to make a good seal between the two,
  • the other end of the second tube body 200 is used to combine with the drug delivery device, thereby completing the manufacture of the drug delivery tube and the combination of the drug delivery tube and the drug delivery device.
  • the outer diameter size ranges between 350-360 ⁇ m, and the outer diameter size range is between 180-190 ⁇ m, making the entire first tube body 100 very thin. After the zone, the damage to the brain tissue of the first tube body 100 is greatly reduced.
  • the second tube 200 is located outside the brain, and its inner diameter is not less than the outer diameter of the first tube 100, and because the first tube 100 needs to be connected to the second tube 200, the inner diameter of the second tube 200
  • the difference between the outer diameter of the first tube body 100 and the outer diameter of the first tube body 100 will not be too large to ensure a sealed connection between the two; in addition, because the tube wall of the second tube body 200 will not be too thick, the second tube body 200
  • the outer diameter size will also be relatively small. Therefore, the drug delivery tube provided in the present application can be implanted into multiple brain regions at the same time to meet the requirement of simultaneously administering multiple brain regions.
  • the drug delivery tube provided in this embodiment only includes the first tube body 100 and the second tube body 200 that are connected to each other, so that the overall structure of the drug delivery tube is simple and the cost is low. In addition, during use, due to the structure Simple and convenient to operate.
  • the outer diameter of the second tube body 200 is in the range of 900-1100 ⁇ m, and the inner diameter is in the range of 450-550 ⁇ m.
  • the outer diameter of the first tube body 100 is 356 ⁇ m and the inner diameter is 182 ⁇ m; and/or, the outer diameter of the second tube body 200 is 1000 ⁇ m and the inner diameter is 500 ⁇ m.
  • the diameter and size of the drug delivery tube in this embodiment is greatly reduced, thereby not only can reduce the damage to the brain tissues implanted in the brain area, but also facilitate the simultaneous administration of multiple brain areas , Or combined with light stimulation or combined with electrophysiological recording methods.
  • one end of the first tube body 100 can be inserted into the second tube body 200, and the distance between the first tube body 100 and the second tube body 200 is 5 mm.
  • first tube body 100 and the second tube body 200 are connected by a sealant.
  • connection mode of the first tube body 100 and the second tube body 200 is specifically as follows:
  • the first tube body 100 can be inserted into the second tube body 200.
  • the gap between the two after insertion will be relatively large, and the drug injection will be affected when the drug is injected later.
  • the accuracy of the amount; that is, the first tube body 100 and the second tube body 200 must be sealed well without any gaps. Otherwise, it is impossible to accurately inject a small amount of medicine.
  • the gap between the first tube body 100 and the second tube body 200 needs to be sealed.
  • a small amount of 502 is used to fix the two together, and then the 502 is dried.
  • the sealant seals the gap, and it is preferable here to use the peerless double glue for sealing.
  • the size of the first tube body 100 inserted into the second tube body 200 is 5mm, and then the gap between the two is sealed by a sealant to ensure that the connection between the two is stronger and at the same time good The tightness.
  • the cut length dimension of the first tube body 100 is 1 cm larger than the depth dimension of the implanted brain region
  • the cut length of the second tube body 200 is 3 cm.
  • the first tube body 100 and the second tube body 200 need to be cut according to the actual situation when making the drug delivery tube. Considering that the first tube body 100 needs to be inserted into the second tube body 200 by 5 mm, and to facilitate implantation It needs to fall outside the brain for insertion and fixation. Therefore, the first tube body 100 in this embodiment can be divided into a segment implanted in the brain, a segment inserted into the second tube body 200, and a segment exposed outside the brain. Preferably, the length of the segment exposed outside the brain is 5 mm, so that the length of the first tube body 100 needs to be 1 cm longer than the implanted brain segment.
  • the first tube body 100 is a silicon tube, a glass tube or a polymer tube, preferably a silicon tube;
  • the second tube body 200 is a plastic tube or a rubber tube, preferably a rubber tube.
  • the first tube body 100 in this embodiment, adopts a silicon tube or a glass tube. , Polymer tube and other tube bodies of relatively hard material, so as to facilitate the implantation of the first tube body 100 into the brain region without deformation.
  • a silicon tube is used to ensure that the first tube body 100 has sufficient hardness when implanted in the brain region and is not easily deformed.
  • the second tube 200 since the second tube 200 is exposed outside the brain, it does not need to be implanted in the brain area, and the first tube 100 and the drug delivery device need to be connected. Therefore, the second tube 200 can be made of softer materials. , Such as a plastic tube, a rubber tube, etc., in this embodiment, a rubber tube is preferably used so as to be sleeved on the first tube body 100 and connected with the drug delivery device.
  • the drug delivery device includes at least a syringe, and the output end of the syringe is used to connect with the end of the second tube 200 away from the first tube 100, so that the drug can be injected through the syringe. It is injected into the brain area through the second tube body 200 and the first tube body 100 in turn to realize the drug delivery behavior to the brain region.
  • This embodiment provides a drug delivery device, including the drug delivery tube in the first embodiment above. Therefore, the technical advantages achieved by the drug delivery device include the technical advantages achieved by the drug delivery tube, which will not be repeated here. .
  • This embodiment provides a neuropsychiatric disease treatment system, including the drug delivery device in the second embodiment;
  • it can also be combined with optical fiber for optical stimulation, or combined with different types of electrodes for electrophysiological recording, or even combined for optical stimulation and electrophysiological recording at the same time, making the application range wider.
  • the sizes of the first tube body 100 and the second tube body 200 in the above-mentioned embodiment are not limited to this, and the experimenter can also adjust the size according to their own experimental purposes, but the first tube body 100 and The thickness of the second tube body 200 should not be too different, otherwise it will not be easy to achieve sealing, which will result in late drug injection or inaccurate measurement, which will eventually lead to experiment failure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

一种给药管、给药装置及神经精神疾病治疗系统，涉及医用器械、神经科学等技术领域。该给药管包括相互密封连接的第一管体（100）和第二管体（200）；该第一管体（100）用于植入到脑区内，第一管体（100）的外径范围为350-360μm，内径范围为180-190μm；第二管体（200）用于与药物送入器件连接，第二管体（200）的硬度小于第一管体（100）的硬度，第二管体（200）的内径不小于第一管体（100）的外径，解决了现有给药管尺寸较大而不方便使用的技术问题，达到了方便使用、结构简单，使用范围广的技术效果。

Description

给药管、给药装置及神经精神疾病治疗系统 技术领域
本申请涉及医用器械、神经科学等技术领域，尤其是涉及一种给药管、给药装置及神经精神疾病治疗系统。
背景技术
近年来，脑科学迅速发展，其中对于神经精神疾病的研究更是热火朝天，然而这仍是人类所面临的最复杂最难以解决的问题。因此科学家们希望能研究出癫痫、抑郁症、精神分裂症等神经精神疾病的发病机制，进而探讨出更加有效的临床治疗靶点以及参数。然而在研究过程中，最大的难点之一就是开发新的研究技术和研究方法来帮助神经科学家绘制大脑环路更清晰的图谱，从而更加全面、深入地理解大脑的功能，实现对脑神经活动高时空分辨率下的精确调控。最终帮助人们了解大脑的认知、情感、记忆等功能的处理机制，以及为神经精神疾病的治疗铺平道路。
在神经科学领域中，为了实现对特定脑区的特定细胞类型进行调控，通常用到的方法有光遗传学和药物遗传学。其中在药物遗传学中，我们需要提前将特异性表达在特定类型神经元上的病毒注射到实验动物脑内。表达四周后通过在实验动物研究的脑区上方植入给药管，利用微量注射泵注射药物到脑内，从而实现对该脑区的特异性调控。
目前，很多公司已经有成品的给药管，这些给药管需要在植入之后扣上一个小帽子，整个小帽子的尺寸较大，如果仅仅是需要在特定的一个脑区给药，这种成品的给药管是完全满足需求的。然而，如果想同时在多个脑区给药或者是结合光刺激或者结合电生理记录的方案，这种给药管就不方便了，因为其尺寸较大，无法同时植入两个及以上给药管，或者给药管无法结合光纤而同时进行给药和光刺激过程，或者给药管无法结合不同种类的电极而同时进行给药和电生理记录过程等。
发明内容
本申请的目的在于提供一种给药管、给药装置及神经精神疾病治疗系统，以缓解上述至少一个问题。
本申请提供一种给药管，包括：相互密封连接的第一管体和第二管体；
所述第一管体用于植入到脑区内，所述第一管体的外径范围为350-360μm，内径范围为180-190μm；
所述第二管体用于与药物送入器件连接，所述第二管体的硬度小于所述第一管体的硬度，所述第二管体的内径不小于所述第一管体的外径。
进一步的，所述第二管体的外径范围为900-1100μm，内径范围为450-550μm。
进一步的，所述第一管体的外径为356μm，内径为182μm；
和/或，所述第二管体的外径为1000μm，内径为500μm。
进一步的，所述第一管体的一端能够插接于所述第二管体内，且所述第一管体插入所述第二管体的深度为5mm。
进一步的，所述第一管体与所述第二管体通过密封胶连接。
进一步的，所述第一管体的截取长度尺寸比植入脑区深度尺寸大1cm；
和/或，所述第二管体的截取长度为3cm。
进一步的，所述第一管体为硅管、玻璃管或多聚物管，优选为硅管；
和/或，所述第二管体为塑料管或橡胶管，优选为橡胶管。
进一步的，所述药物送入器件至少包括注射器，所述注射器的输出端用于与所述第二管体远离所述第一管体的端部连接。
本申请提供一种给药装置，包括所述的给药管。
本申请提供一种神经精神疾病治疗系统，包括所述的给药装置；
或者，包括电生理记录装置和给药装置；
或者，包括光刺激装置和给药装置；
或者包括电生理记录装置、光刺激装置和给药装置。
本申请提供的一种给药管具有如下优点：
本申请中，第一管体用于植入脑区内，由于其尺寸较小，外径范围仅为350-360μm，内径范围仅为180-190μm，使的给药管植入脑区内的一段很细，由此，植入后对脑组织的损伤会很小。
优选地，第二管体位于脑外，其内径尺寸不小于第一管体的外径尺寸，且由于第一管体需要与第二管体连接，使得第二管体的内径与第一管体外径之间的差值不会太大，以保证两者之间的密封连接；另外，由于第二管体的管壁不会太厚，使得第二管体外径尺寸也会相对较小，由此，本申请提供的给药管能够同时植入多个脑区，满足同时给多个脑区给药的要求。
优选地，该给药管仅包括相互密封连接在一起的第一管体和第二管体，使得给药管整体结构简单，成本较低，并且，在使用过程中，由于结构简单，操作起来也比较方便。
本申请提供的一种给药装置，包括上述给药管，由此，该给药装置所达到的技术优势包括上述给药管所达到的技术优势，此处不再赘述。
本申请提供的一种神经精神疾病治疗系统，包括上述给药装置，当然，还可以包括电生理记录装置及光刺激装置中的至少一种，由此，除了包括上述给药装置所达到的技术优势之外，还可以结合光纤进行光刺激或者结合不同种类的电极进行电生理记录，甚至同时结合进行光刺激和电生理记录，使应用范围更广泛。
附图说明
为了更清楚地说明本申请具体实施方式或现有技术中的技术方案，下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图是本申请的一些实施方式，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1为本申请实施例提供的给药管的结构示意图。
图标：100-第一管体；200-第二管体。
具体实施方式
下面将结合实施例对本申请的技术方案进行清楚、完整地描述，显然，所描述的实施例是本申请一部分实施例，而不是全部的实施例。基于本申请中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本申请保护的范围。
实施例一
本实施例提供了一种给药管，包括相互密封连接的第一管体100和第二管体200；
第一管体100用于植入到脑区内，第一管体100的外径范围为350-360μm，内径范围为180-190μm；
第二管体200用于与药物送入器件连接，第二管体200的硬度小于第一管体100的硬度，第二管体200的内径不小于第一管体100的外径。
具体的，本实施例中的给药管包括相互连接的第一管体100和第二管体200，在使用过程中，第一管体100植入到脑区内一段，并遗留一段露在脑外，由于第一管体100的外径尺寸比较小，很方便植入脑区内，而露在脑外的一段又很方便进行固定。
第二管体200则完全露在脑外，且第二管体200上未连接第一管体100的一端部与微量的药物送入器件结合，这样一来，通过药物送入器件能够将药物依次通过第二导管、第一导管注射到脑区内。
需要说明的是，第一管体100和第二管体200均采用细管结构，且这两种细管还可以采用现有的成品，或直接购买，或采用定制，具体情况需要实验人员按照自己的实验需求设计即可。
本实施例中还提供了给药管的制作步骤、方法，具体如下：
根据实际需要截取一定长度的第一管体100，以及截取一定长度的第二管体200，然后将第一管体100与第二管体200的一端连接，并使两者之间密封良好，而第二管体200的另一端用于与药物送入器件结合，由此，完成了给药管的制作以及给药管与药物送入器件的结合。
本实施例提供的给药管具有如下优点：
由于第一管体100的尺寸很小，外径尺寸范围在350-360μm之间，外径尺寸范围在180-190μm之间，使得整个第一管体100非常细，由此，在植入脑区后，大大降低了第一管体100对脑组织的损伤。
并且，第二管体200位于脑外，其内径尺寸不小于第一管体100的外径尺寸，且由于第一管体100需要与第二管体200连接，使得第二管体200的内径与第一管体100外径之间的差值不会太大，以保证两者之间的密封连接；另外，由于第二管体200的管壁不会太厚，使得第二管体200外径尺寸也会相对较小，由此，本申请提供的给药管能够同时植入多个脑区，满足同时给多个脑区给药的要求。
另外，本实施例提供的给药管仅包括相互连接在一起的第一管体100和第二管体200，使得给药管整体结构简单，成本较低，并且，在使用过程中，由于结构简单，操作起来也比较方便。
本实施例的可选技术方案中，第二管体200的外径范围为900-1100μm，内径范围为450-550μm。
进一步优选地，第一管体100的外径为356μm，内径为182μm；和/或，第二管体200的外径为1000μm，内径为500μm。
需要说明的是，基于上述第一管体100与第二管体200的具体尺寸可知，相比于现有技术中的给药管在植入之后需要扣上一个小帽子，而整个小帽子的尺寸较大，本实施例中的给药管的直径尺寸大幅度减小，从而，既能够减小植 入脑区内对脑组织的损伤，同时还能够方便实施同时对多个脑区给药，或是结合光刺激或结合电生理记录的方法。
本实施例的可选技术方案中，第一管体100的一端能够插接于第二管体200内，且第一管体100插入第二管体200的距离为5mm。
本实施例的可选技术方案中，第一管体100与第二管体200通过密封胶连接。
本实施例中，第一管体100与第二管体200的连接方式具体如下：
由于第二管体200的内径不小于第一管体100的外径尺寸，使得第一管体100能够插入到第二管体200中。而当第二管体200的内径尺寸与第一管体100的外径尺寸之间的差值较大时，插入后两者之间的间隙会比较大，后期在注药物时会影响药物注射量的精确度；即，第一管体100与第二管体200之间一定要密封好，不能有任何缝隙，不然后期无法精确注射微量的药物。
基于上述问题，本实施例中需要对第一管体100与第二管体200之间的间隙进行密封，优选为，先用少量的502将两者固定在一起，等502干了之后再用密封胶对间隙实现密封，此处优选的，采用绝代双胶密封。
进一步优选地，第一管体100插入第二管体200内的尺寸为5mm，然后再通过密封胶将两者之间的缝隙进行密封，以保证两者之间的连接更加牢固，同时保证良好的密封性。
本实施例的可选技术方案中，第一管体100的截取长度尺寸比植入脑区深度尺寸大1cm；
和/或，第二管体200的截取长度为3cm。
本实施例中，在制作给药管首先需要根据实际情况截取第一管体100和第二管体200，考虑到第一管体100需要插入到第二管体200内5mm，以及为了方便植入和固定而需要落在脑外一段，由此，本实施例中的第一管体100可分 为植入脑区段、插入第二管体200段和露在脑外段。优选地，露在脑外段长度为5mm，从而，第一管体100截取的长度需要比植入脑区段长1cm。
本实施例的可选技术方案中，第一管体100为硅管、玻璃管或多聚物管，优选为硅管；
和/或，第二管体200为塑料管或橡胶管，优选为橡胶管。
需要说明的是，为将第一管体100的一端植入脑区内，需要第一管体100具有一定的硬度，由此，本实施例中的第一管体100采用硅管、玻璃管、多聚物管等硬度较大材质的管体，以利于第一管体100植入脑区内而不会发生形变。本实施例中优选地，采用硅管，以保证第一管体100植入脑区内时具有足够的硬度而不易变形。
另外，由于第二管体200露在脑外，不需要植入脑区内，并且，需要连接第一管体100以及药物送入器件，由此，第二管体200可以使用较软的材质，如塑料管、橡胶管等，本实施例中优选地，采用橡胶管，以便于套接在第一管体100上，以及与药物送入器件实现连接。
本实施例的可选技术方案中，药物送入器件至少包括注射器，注射器的输出端用于与第二管体200远离第一管体100的端部连接，由此，通过注射器能够将药液依次经过第二管体200、第一管体100注射到脑区内，实现对脑区的给药行为。
实施例二
本实施例提供了一种给药装置，包括上述实施例一中的给药管，由此，该给药装置所达到的技术优势包括上述给药管所达到的技术优势，此处不再赘述。
实施例三
本实施例提供了一种神经精神疾病治疗系统，包括实施例二中的给药装置；
或者包括电生理记录装置和给药装置，或者包括光刺激装置和给药装置，或者包括电生理记录装置、光刺激装置和给药装置，由此，除了包括上述给药装置所达到的技术优势之外，还可以结合光纤进行光刺激或者结合不同种类的电极进行电生理记录，甚至同时结合进行光刺激和电生理记录，使应用范围更广泛。
需要说明的是，关于通过电生理记录装置实现电生理实验的过程或原理，以及通过给药管或给药装置实现的给药行为结合不同种类的电极进行电生理实验均可以参考现有技术，此处不做详细阐述。
另外，关于通过光刺激装置实现光刺激实验的过程或原理，以及通过给药管或给药装置实现的给药行为结合光纤进行光刺激均可以参考现有技术，此处不做详细阐述。
另外，通过给药管或给药装置实现的给药行为、结合光纤进行光刺激以及结合不同种类的电极进行电生理实验三者之间同时进行的过程或原理同样可以参考现有技术，此处不做详细阐述。
此外，还需说明的是，上述实施例中的第一管体100和第二管体200的尺寸并不限于此，实验人员还可以根据自己的实验目的自行调整，但是第一管体100与第二管体200的粗细相差不能太大，否则不容易实现密封，而导致后期药物注射不进去或者计量不准确，最终导致实验失败。
最后应说明的是：以上各实施例仅用以说明本申请的技术方案，而非对其限制；尽管参照前述各实施例对本申请进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本申请各实施例技术方案的范围。

Claims (10)

  1. 一种给药管，其特征在于，包括：相互密封连接的第一管体(100)和第二管体(200)；
    所述第一管体(100)用于植入到脑区内，所述第一管体(100)的外径范围为350-360μm，内径范围为180-190μm；
    所述第二管体(200)用于与药物送入器件连接，所述第二管体(200)的硬度小于所述第一管体(100)的硬度，所述第二管体(200)的内径不小于所述第一管体(100)的外径。
  2. 根据权利要求1所述的给药管，其特征在于，所述第二管体(200)的外径范围为900-1100μm，内径范围为450-550μm。
  3. 根据权利要求2所述的给药管，其特征在于，所述第一管体(100)的外径为356μm，内径为182μm；
    和/或，所述第二管体(200)的外径为1000μm，内径为500μm。
  4. 根据权利要求1-3任一项所述的给药管，其特征在于，所述第一管体(100)的一端能够插接于所述第二管体(200)内，且所述第一管体(100)插入所述第二管体(200)的深度为5mm。
  5. 根据权利要求4所述的给药管，其特征在于，所述第一管体(100)与所述第二管体(200)通过密封胶连接。
  6. 根据权利要求4所述的给药管，其特征在于，所述第一管体(100)的截取长度尺寸比植入脑区深度尺寸大1cm；
    和/或，所述第二管体(200)的截取长度为3cm。
  7. 根据权利要求1-3任一项所述的给药管，其特征在于，所述第一管体(100)为硅管、玻璃管或多聚物管；
    和/或，所述第二管体(200)为塑料管或橡胶管。
  8. 根据权利要求1所述的给药管，其特征在于，所述药物送入器件至少包括注射器，所述注射器的输出端用于与所述第二管体(200)远离所述第一管体(100)的端部连接。
  9. 一种给药装置，其特征在于，包括权利要求1-8任一项所述的给药管。
  10. 一种神经精神疾病治疗系统，其特征在于，包括权利要求9所述的给 药装置；
    或者，包括电生理记录装置和权利要求9所述的给药装置；
    或者，包括光刺激装置和权利要求9所述的给药装置；
    或者，包括电生理记录装置、光刺激装置和权利要求9所述的给药装置。
PCT/CN2019/123177 2019-08-14 2019-12-05 给药管、给药装置及神经精神疾病治疗系统 Ceased WO2021027192A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201921314556.2U CN211068689U (zh) 2019-08-14 2019-08-14 给药管、给药装置及神经精神疾病治疗系统
CN201921314556.2 2019-08-14

Publications (1)

Publication Number Publication Date
WO2021027192A1 true WO2021027192A1 (zh) 2021-02-18

Family

ID=71635183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/123177 Ceased WO2021027192A1 (zh) 2019-08-14 2019-12-05 给药管、给药装置及神经精神疾病治疗系统

Country Status (2)

Country Link
CN (1) CN211068689U (zh)
WO (1) WO2021027192A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199128A1 (en) * 2000-03-31 2004-10-07 Medtronic, Inc. Catheter for target specific drug delivery
CN1891310A (zh) * 2005-07-04 2007-01-10 中国科学院心理研究所 一种适用于神经科学研究的植入式颅内给药插管
US20070088295A1 (en) * 2005-08-23 2007-04-19 Bankiewicz Krystof S Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
EP1738790B1 (en) * 2005-06-27 2007-10-17 Lars-Olof Hattenbach Device for the injection of drugs into microvessels
CN101951989A (zh) * 2008-02-13 2011-01-19 瑞尼斯豪(爱尔兰)有限公司 导管

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199128A1 (en) * 2000-03-31 2004-10-07 Medtronic, Inc. Catheter for target specific drug delivery
EP1738790B1 (en) * 2005-06-27 2007-10-17 Lars-Olof Hattenbach Device for the injection of drugs into microvessels
CN1891310A (zh) * 2005-07-04 2007-01-10 中国科学院心理研究所 一种适用于神经科学研究的植入式颅内给药插管
US20070088295A1 (en) * 2005-08-23 2007-04-19 Bankiewicz Krystof S Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
CN101951989A (zh) * 2008-02-13 2011-01-19 瑞尼斯豪(爱尔兰)有限公司 导管

Also Published As

Publication number Publication date
CN211068689U (zh) 2020-07-24

Similar Documents

Publication Publication Date Title
JP4871492B2 (ja) 流体移送用医療用コネクタアッセンブリ
AU2017206114A1 (en) Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
JP2014531463A (ja) 瘻治療のための組成物
RU2017113354A (ru) Инъекционные микрочастицы для сверхлокализованного высвобождения терапевтических средств
US11511095B2 (en) Portable transdermal administration patch apparatus and preparation method thereof
KR102689935B1 (ko) 카테터 없이 요도를 통해 방광 내로 약제를 주사하기 위한 어댑터, 방법 및 용도
RU2485982C1 (ru) Устройство и способы улучшенной многократной доставки биологически активных веществ внутрь организма и для предотвращения местного раздражения
JP2018527131A5 (zh)
CN104353183B (zh) 电解液位置固定的可佩戴智能药物导入结构
CN211068689U (zh) 给药管、给药装置及神经精神疾病治疗系统
CN105816270A (zh) 一种耳道给药器
CN115089851A (zh) 一种可持续给药的人工耳蜗植入体
CN209301966U (zh) 动物实验中插管用导管
WO2023231388A1 (zh) 一种用于治疗男性前列腺炎的药物及其应用
CN210813439U (zh) 鼻腔嗅裂区精准给药装置
WO2019205285A1 (zh) 植入式超声波传导及药物投送装置
CN211798196U (zh) 一种便于定量给药的肛肠外科自动给药装置
CN219271922U (zh) 给药位置可调式鼻腔给药装置
CN109513092B (zh) 动物实验中插管用导管、输注给药装置及动物试验模型
CN216725412U (zh) 一种输液港
CN209270606U (zh) 骨科植入式给药装置
CN115317773A (zh) 向鼻腔滴注药物的装置
CN205339828U (zh) 泌尿及生殖系统给药器
CN101032643A (zh) 内耳圆窗膜给药器
CN209630432U (zh) 一种皮下植入式给药装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19941590

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19941590

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 19941590

Country of ref document: EP

Kind code of ref document: A1